Form 4: Tyra Biosciences CEO Todd Harris Sells 500 Shares
SEC Form 4 Filing
Tyra Biosciences CEO Todd Harris sold 500 shares of common stock at $24 per share on September 30, 2024, according to a Form 4 filing.
Summary
- On September 30, 2024, Todd Harris, the President and CEO of Tyra Biosciences, sold 500 shares of common stock.
- The sale was executed at a price of $24 per share.
- Following the transaction, Harris directly owns 1,477,373 shares of Tyra Biosciences.
- The sale was conducted under a Rule 10b5-1 trading plan adopted in December 2022.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine stock sale by an executive under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.
Industry Context
Insider sales are a common occurrence and are often viewed in the context of pre-planned trading programs like Rule 10b5-1 plans, which allow insiders to sell shares over a period of time to avoid accusations of trading on material non-public information.
Stakeholder Impact
- The sale of shares by the CEO could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| December 2022 | Date of adoption of Rule 10b5-1 trading plan |
| 09/30/2024 | Date of transaction: Sale of 500 shares |
| 10/02/2024 | Date of filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.